| Study | Reason for exclusion |
|---|---|
| ACTIV‐2 | SARS‐CoV‐2‐specific mAb examined for treatment. |
| ACTIV‐3 | SARS‐CoV‐2‐specific mAb examined for treatment. |
| BLAZE‐1 | SARS‐CoV‐2‐specific mAb examined for treatment. |
| BLAZE‐4 | SARS‐CoV‐2‐specific mAb examined for treatment. |
| COMET‐ICE | SARS‐CoV‐2‐specific mAb examined for treatment. |
| Eom 2021 | SARS‐CoV‐2‐specific mAb examined for treatment. |
| Kim 2021 | SARS‐CoV‐2‐specific mAb examined for treatment. |
| NCT04411628 | SARS‐CoV‐2‐specific mAb examined for treatment. |
| NCT04426695 | SARS‐CoV‐2‐specific mAb examined for treatment. |
| NCT04666441 | SARS‐CoV‐2‐specific mAb examined for treatment. |
| NCT04931238 | SARS‐CoV‐2‐specific mAb examined for treatment. |
| OPTIMISE‐C19 | SARS‐CoV‐2‐specific mAb examined for treatment. |
| RECOVERY | SARS‐CoV‐2‐specific mAb examined for treatment. |
| Weinreich | SARS‐CoV‐2‐specific mAb examined for treatment. |
mAb: monoclonal antibody; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2.